RAD140 not checked

Stemline Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“RAD140 will be supplied as formulated drug-in-capsules for oral administration.”In the company’s words, NCT03088527 on ClinicalTrials.gov
Tested for
Hormone Receptor Positive Malignant Neoplasm of Breast
Main trialPhase 1
“The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.”In the company’s words, NCT03088527 on ClinicalTrials.gov

Other drugs for Hormone Receptor Positive Malignant Neoplasm of Breast

All 397 drugs for Hormone Receptor Positive Malignant Neoplasm of Breast

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 28 Aug 2020 Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow RAD140

Following is part of Solo: you see every change to RAD140 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in